Dominika Dutkiewicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dominika Dutkiewicz has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Julia Mądrzak
Faculty of Medicine, Kazimierz Pułaski University of Radom, Radom, Poland
10 shared publications - Klaudia Jurkowska
Medical University of Silesia in Katowice, Katowice, Poland
10 shared publications - Jakub Fidelus
Medical University of Lodz, Łódź, Poland
9 shared publications - Julia Czerniewska
Medical University of Silesia in Katowice, Katowice, Poland
9 shared publications - Magdalena Filuk
Collegium Medicum in Bydgoszcz, Bydgoszcz, Kujawsko-Pomorskie, Poland
9 shared publications - Marianna Ciastoń
Medical University of Silesia in Katowice, Katowice, Poland
9 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Institute of Rural Health in Medycyna Ogólna i Nauki o Zdrowiu
Nutrigenomics and epigenetics in type 2 diabetes mellitus (T2DM) prevention – literature review
Introduction and objective: Type 2 diabetes mellitus affects more than 500 million adults worldwide and continues to increase. Diet shapes molecular pathways regulating insulin sensitivity, inflammation and glucose metabolism. Nutrigenomics studies nutrient-gene interactions,...
- 20 August 2026
- Published by Institute of Rural Health in Medycyna Ogólna i Nauki o Zdrowiu
Open AccessNutrigenomics and epigenetics in type 2 diabetes mellitus (T2DM) prevention – literature review
Introduction and objective: Type 2 diabetes mellitus affects more than 500 million adults worldwide and continues to increase. Diet shapes molecular pathways regulating insulin sensitivity, inflammation and glucose metabolism. Nutrigenomics studies nutrient-gene interactions,...
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
BEYOND WEIGHT LOSS: THE DUAL IMPACT OF GLP-1 AND DUAL GIP/GLP-1 RECEPTOR AGONISTS ON THE SKIN A SYSTEMATIC REVIEW OF SAFETY, ADVERSE REACTIONS, AND THERAPEUTIC POTENTIAL IN INFLAMMATORY DERMATOSES
Background: The emergence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists has fundamentally altered the therapeutic landscape for type 2 diabetes and obesity. Beyond their metabolic and cardiovascular benefits, these agents exert a profound, yet under-recognized, influence on the skin. This systematic review evaluates the "dual impact" of these therapies: their cutaneous safety profile and their emerging therapeutic potential in chronic inflammatory skin diseases. Methods: A systematic analysis was conducted utilizing data from landmark clinical trials, including the STEP, SURPASS, and SURMOUNT programs, alongside real-world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS). The study analyzed dermatologic outcomes and safety signals in a cohort of over 50,000 patients. Results: Findings indicate that while injection-site reactions and mild hypersensitivity are common, rare but serious signals such as bullous pemphigoid and systemic allergic reactions require clinical vigilance. Paradoxically, the potent anti-inflammatory effects of these drugs, mediated through the modulation of the IL-23/IL-17 axis and adipose tissue-derived cytokines, offer significant therapeutic benefits for psoriasis and hidradenitis suppurativa. Furthermore, rapid weight loss induces unique aesthetic changes, including significant facial volume loss, colloquially known as "Ozempic Face." Conclusions: Incretin-based therapies represent a novel intersection of metabolic medicine and dermatology. A multidisciplinary approach is essential to optimize patient care and safety, balancing the management of cutaneous adverse events with the clinical leverage of the drugs’ immunomodulatory potential in inflammatory dermatoses.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessBEYOND WEIGHT LOSS: THE DUAL IMPACT OF GLP-1 AND DUAL GIP/GLP-1 RECEPTOR AGONISTS ON THE SKIN A SYSTEMATIC REVIEW OF SAFETY, ADVERSE REACTIONS, AND THERAPEUTIC POTENTIAL IN INFLAMMATORY DERMATOSES
Background: The emergence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists has fundamentally altered the therapeutic landscape for type 2 diabetes and obesity. Beyond their metabolic and cardiovascular benefits, these agents exert a profound, yet under-recognized, influence on the skin. This systematic review evaluates the "dual impact" of these therapies: their cutaneous safety profile and their emerging therapeutic potential in chronic inflammatory skin diseases. Methods: A systematic analysis was conducted utilizing data from landmark clinical trials, including the STEP, SURPASS, and SURMOUNT programs, alongside real-world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS). The study analyzed dermatologic outcomes and safety signals in a cohort of over 50,000 patients. Results: Findings indicate that while injection-site reactions and mild hypersensitivity are common, rare but serious signals such as bullous pemphigoid and systemic allergic reactions require clinical vigilance. Paradoxically, the potent anti-inflammatory effects of these drugs, mediated through the modulation of the IL-23/IL-17 axis and adipose tissue-derived cytokines, offer significant therapeutic benefits for psoriasis and hidradenitis suppurativa. Furthermore, rapid weight loss induces unique aesthetic changes, including significant facial volume loss, colloquially known as "Ozempic Face." Conclusions: Incretin-based therapies represent a novel intersection of metabolic medicine and dermatology. A multidisciplinary approach is essential to optimize patient care and safety, balancing the management of cutaneous adverse events with the clinical leverage of the drugs’ immunomodulatory potential in inflammatory dermatoses.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
SWITCHING BETWEEN ANTI-VEGF AGENTS IN DIABETIC MACULAR EDEMA: A NARRATIVE REVIEW OF EVIDENCE AND CLINICAL PRACTICE
Background: Diabetic macular edema (DME) is a leading cause of vision impairment among patients with diabetic retinopathy. Intravitreal anti–vascular endothelial growth factor (anti-VEGF) therapy has become the first-line treatment; however, a significant proportion of patients demonstrate suboptimal response or require frequent injections, highlighting the need for alternative therapeutic strategies. Objective: To review the rationale, clinical evidence, and outcomes associated with switching between anti-VEGF agents in the management of DME, with a focus on real-world data and emerging therapies. Methods: A narrative review of the literature was conducted, including randomized controlled trials, observational studies, and meta-analyses evaluating anti-VEGF therapy and switching strategies in DME. Particular attention was given to studies assessing treatment response, predictors of outcomes, and newer agents such as faricimab. Results: Evidence suggests that a substantial proportion of patients exhibit incomplete anatomical or functional response to initial anti-VEGF therapy. Switching between agents, particularly from ranibizumab or bevacizumab to aflibercept, has been associated with improvements in retinal thickness and stabilization or modest gains in visual acuity. The introduction of faricimab, a dual inhibitor of VEGF-A and angiopoietin-2, has demonstrated comparable efficacy to aflibercept with extended dosing intervals in phase 3 trials and promising real-world outcomes. Meta-analyses confirm overall effectiveness of anti-VEGF therapy while highlighting variability in individual response. Conclusion: Switching between anti-VEGF agents represents a practical and evidence-based strategy in patients with DME who demonstrate suboptimal response to initial therapy. Emerging treatments such as faricimab further expand therapeutic options and may reduce treatment burden. Individualized treatment approaches and timely therapy modification are essential for optimizing long-term outcomes.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessSWITCHING BETWEEN ANTI-VEGF AGENTS IN DIABETIC MACULAR EDEMA: A NARRATIVE REVIEW OF EVIDENCE AND CLINICAL PRACTICE
Background: Diabetic macular edema (DME) is a leading cause of vision impairment among patients with diabetic retinopathy. Intravitreal anti–vascular endothelial growth factor (anti-VEGF) therapy has become the first-line treatment; however, a significant proportion of patients demonstrate suboptimal response or require frequent injections, highlighting the need for alternative therapeutic strategies. Objective: To review the rationale, clinical evidence, and outcomes associated with switching between anti-VEGF agents in the management of DME, with a focus on real-world data and emerging therapies. Methods: A narrative review of the literature was conducted, including randomized controlled trials, observational studies, and meta-analyses evaluating anti-VEGF therapy and switching strategies in DME. Particular attention was given to studies assessing treatment response, predictors of outcomes, and newer agents such as faricimab. Results: Evidence suggests that a substantial proportion of patients exhibit incomplete anatomical or functional response to initial anti-VEGF therapy. Switching between agents, particularly from ranibizumab or bevacizumab to aflibercept, has been associated with improvements in retinal thickness and stabilization or modest gains in visual acuity. The introduction of faricimab, a dual inhibitor of VEGF-A and angiopoietin-2, has demonstrated comparable efficacy to aflibercept with extended dosing intervals in phase 3 trials and promising real-world outcomes. Meta-analyses confirm overall effectiveness of anti-VEGF therapy while highlighting variability in individual response. Conclusion: Switching between anti-VEGF agents represents a practical and evidence-based strategy in patients with DME who demonstrate suboptimal response to initial therapy. Emerging treatments such as faricimab further expand therapeutic options and may reduce treatment burden. Individualized treatment approaches and timely therapy modification are essential for optimizing long-term outcomes.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
ORAL HEALTH EFFECTS OF NICOTINE POUCHES: A SYSTEMATIC NARRATIVE REVIEW WITH CONTEXTUALIZATION AGAINST CONVENTIONAL TOBACCO PRODUCTS
Background: Nicotine pouches are tobacco-free oral nicotine delivery products placed in the oral vestibule without combustion or tobacco leaf contact. Despite accelerating global market expansion and the 2025 U.S. Food and Drug Administration (FDA) marketing authorization, their oral health consequences remain poorly characterized. Objective: This systematic narrative review synthesizes available clinical and mechanistic evidence on the oral health effects of nicotine pouches across four domains: oral mucosal changes, periodontal status, dental caries, and oral cancer risk. Methods: A systematic search of PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, Embase, and Google Scholar was conducted (last updated March 2026). Ten eligible studies published between 2021 and 2026 were identified and appraised using design-appropriate quality tools. Evidence was synthesized narratively across four clinical and mechanistic domains. Results: Evidence consistently documents localized gingival recession and leukoplakia at vestibular pouch-placement sites, with severity appearing lower than traditional snus. Periodontal clinical data are absent, though mechanistic evidence for nicotine-driven periodontal injury is robust. Nicotine promotes Streptococcus mutans virulence, induces oral microbiome dysbiosis, and impairs salivary function. No epidemiological data on oral cancer incidence in nicotine pouch users exist; however, mechanistic evidence demonstrates multi-pathway oncogenic potential of nicotine independently of tobacco-specific nitrosamines. Conclusions: Nicotine pouches are not orally safe. Available evidence suggests a tentative harm-reduction gradient relative to cigarettes for mucosal outcomes when data are contextualized indirectly, but direct clinical comparisons between nicotine pouch users and cigarette smokers are virtually absent, and critical evidence gaps persist across all four domains. Long-term independent prospective studies are urgently required.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessORAL HEALTH EFFECTS OF NICOTINE POUCHES: A SYSTEMATIC NARRATIVE REVIEW WITH CONTEXTUALIZATION AGAINST CONVENTIONAL TOBACCO PRODUCTS
Background: Nicotine pouches are tobacco-free oral nicotine delivery products placed in the oral vestibule without combustion or tobacco leaf contact. Despite accelerating global market expansion and the 2025 U.S. Food and Drug Administration (FDA) marketing authorization, their oral health consequences remain poorly characterized. Objective: This systematic narrative review synthesizes available clinical and mechanistic evidence on the oral health effects of nicotine pouches across four domains: oral mucosal changes, periodontal status, dental caries, and oral cancer risk. Methods: A systematic search of PubMed/MEDLINE, Scopus, Web of Science, Cochrane Library, Embase, and Google Scholar was conducted (last updated March 2026). Ten eligible studies published between 2021 and 2026 were identified and appraised using design-appropriate quality tools. Evidence was synthesized narratively across four clinical and mechanistic domains. Results: Evidence consistently documents localized gingival recession and leukoplakia at vestibular pouch-placement sites, with severity appearing lower than traditional snus. Periodontal clinical data are absent, though mechanistic evidence for nicotine-driven periodontal injury is robust. Nicotine promotes Streptococcus mutans virulence, induces oral microbiome dysbiosis, and impairs salivary function. No epidemiological data on oral cancer incidence in nicotine pouch users exist; however, mechanistic evidence demonstrates multi-pathway oncogenic potential of nicotine independently of tobacco-specific nitrosamines. Conclusions: Nicotine pouches are not orally safe. Available evidence suggests a tentative harm-reduction gradient relative to cigarettes for mucosal outcomes when data are contextualized indirectly, but direct clinical comparisons between nicotine pouch users and cigarette smokers are virtually absent, and critical evidence gaps persist across all four domains. Long-term independent prospective studies are urgently required.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
MANDIBULAR MANIFESTATIONS OF SAPHO SYNDROME. A SYSTEMATIC REVIEW
Background: SAPHO syndrome is a rare, long-lasting inflammatory disease. While it usually affects the chest wall and spine, it attacks the lower jaw in about 10% of patients. Because its symptoms closely mimic regular tooth infections, it frequently leads to wrong diagnoses and delayed care. Aim: This study aims to provide a clear, detailed review of SAPHO syndrome in the jaw based on 22 scientific reports. The goal is to describe clinical signs, imaging results, and treatment options, and to compare modern medicines with major surgeries. Results: The most common signs are recurrent severe jaw pain, facial swelling, and severe trismus. Without treatment, the jaw joint can completely fuse or melt away. Early diagnosis requires advanced scans: MRI with a STIR setting is the best tool to find early bone fluid (edema), while CT scans show a characteristic "onion-skin" bone pattern. Traditional treatments like antibiotics offer only short-term relief. Today, modern targeted drugs—such as biologic agents, bisphosphonates, and Yunke (99Tc-MDP)—are used to successfully stop bone damage and calm the immune system. Conclusion: The treatment of SAPHO syndrome in the jaw has shifted from major bone surgery to smart, targeted medicines. Early diagnosis using MRI is critical to avoid pulling healthy teeth. Surgery should only be used to rebuild the face or free a stuck joint after the medicine has stopped the active disease.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
Open AccessMANDIBULAR MANIFESTATIONS OF SAPHO SYNDROME. A SYSTEMATIC REVIEW
Background: SAPHO syndrome is a rare, long-lasting inflammatory disease. While it usually affects the chest wall and spine, it attacks the lower jaw in about 10% of patients. Because its symptoms closely mimic regular tooth infections, it frequently leads to wrong diagnoses and delayed care. Aim: This study aims to provide a clear, detailed review of SAPHO syndrome in the jaw based on 22 scientific reports. The goal is to describe clinical signs, imaging results, and treatment options, and to compare modern medicines with major surgeries. Results: The most common signs are recurrent severe jaw pain, facial swelling, and severe trismus. Without treatment, the jaw joint can completely fuse or melt away. Early diagnosis requires advanced scans: MRI with a STIR setting is the best tool to find early bone fluid (edema), while CT scans show a characteristic "onion-skin" bone pattern. Traditional treatments like antibiotics offer only short-term relief. Today, modern targeted drugs—such as biologic agents, bisphosphonates, and Yunke (99Tc-MDP)—are used to successfully stop bone damage and calm the immune system. Conclusion: The treatment of SAPHO syndrome in the jaw has shifted from major bone surgery to smart, targeted medicines. Early diagnosis using MRI is critical to avoid pulling healthy teeth. Surgery should only be used to rebuild the face or free a stuck joint after the medicine has stopped the active disease.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
BEYOND AESTHETICS: BOTULINUM TOXIN TYPE A AS AN EMERGING ANTIDEPRESSANT STRATEGY
Major depressive disorder remains one of the most burdensome psychiatric conditions worldwide, and a substantial proportion of patients continue to suffer despite available treatments. This narrative review examines an unexpected therapeutic candidate: botulinum toxin type A (BoNT/A), a bacterial neurotoxin long used in aesthetic medicine to reduce facial frown lines, which has emerged as a promising antidepressant intervention. The review synthesises clinical evidence from randomised controlled trials and meta-analyses, alongside mechanistic data from neuroimaging and preclinical studies, to evaluate the efficacy, safety, and biological plausibility of this approach. The findings consistently indicate that a single injection of BoNT/A into the glabellar region produces meaningful and durable improvements in depressive symptoms. The proposed mechanisms are scientifically compelling: by paralysing the muscles responsible for frowning, BoNT/A disrupts a feedback loop between facial expression and emotional processing in the brain, modulates activity in key mood-regulating structures, and triggers neurochemical changes associated with recovery from depression. The treatment is well tolerated, with only mild and transient side effects. Although larger confirmatory trials are needed, BoNT/A represents a genuinely novel, accessible, and mechanistically grounded addition to the therapeutic landscape of depression.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
Open AccessBEYOND AESTHETICS: BOTULINUM TOXIN TYPE A AS AN EMERGING ANTIDEPRESSANT STRATEGY
Major depressive disorder remains one of the most burdensome psychiatric conditions worldwide, and a substantial proportion of patients continue to suffer despite available treatments. This narrative review examines an unexpected therapeutic candidate: botulinum toxin type A (BoNT/A), a bacterial neurotoxin long used in aesthetic medicine to reduce facial frown lines, which has emerged as a promising antidepressant intervention. The review synthesises clinical evidence from randomised controlled trials and meta-analyses, alongside mechanistic data from neuroimaging and preclinical studies, to evaluate the efficacy, safety, and biological plausibility of this approach. The findings consistently indicate that a single injection of BoNT/A into the glabellar region produces meaningful and durable improvements in depressive symptoms. The proposed mechanisms are scientifically compelling: by paralysing the muscles responsible for frowning, BoNT/A disrupts a feedback loop between facial expression and emotional processing in the brain, modulates activity in key mood-regulating structures, and triggers neurochemical changes associated with recovery from depression. The treatment is well tolerated, with only mild and transient side effects. Although larger confirmatory trials are needed, BoNT/A represents a genuinely novel, accessible, and mechanistically grounded addition to the therapeutic landscape of depression.
- Open Access
- 19 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
THE GUT–BRAIN AXIS IN AUTISM SPECTRUM DISORDER: MICROBIOTA, IMMUNE DYSREGULATION, AND THERAPEUTIC PERSPECTIVES
Background: Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by persistent difficulties in social communication, restricted and repetitive behaviors, and a high prevalence of co-occurring gastrointestinal, metabolic, and immune disturbances. Increasing evidence suggests that the gut–brain axis—a bidirectional communication network linking intestinal microbiota, immune signaling, metabolic pathways, and neural circuits—may play an important modulatory role in ASD-related neurodevelopmental processes. Scope: This review synthesizes current evidence on gut–brain axis physiology and examines how alterations in microbiota composition and function intersect with immune dysregulation, microbial metabolite signaling, and neurodevelopment in ASD. Findings from clinical studies, preclinical mechanistic research, and emerging microbiota-targeted therapeutic approaches are integrated to provide a systems-level perspective on microbiota–immune–brain interactions. Key Findings: Individuals with ASD frequently exhibit altered gut microbial diversity and composition, accompanied by functional disruptions in microbial metabolite pathways, including short-chain fatty acid and tryptophan metabolism. These changes are associated with impaired intestinal barrier integrity, systemic immune activation, neuroinflammatory signaling, and microglial dysfunction, processes that may contribute to excitatory–inhibitory imbalance and altered synaptic plasticity in the central nervous system. Microbiota-targeted interventions—such as probiotics, dietary modification, and fecal microbiota transplantation—demonstrate preliminary benefits for gastrointestinal symptoms and selected behavioral outcomes, although clinical evidence remains heterogeneous and limited. Conclusions: Current evidence supports a multifactorial model in which gut microbiota alterations act as modulatory amplifiers of neurodevelopmental vulnerability in ASD rather than as primary causal factors. Interactions among microbial metabolism, immune regulation, environmental exposures, and developmental timing appear central to this process. Future progress will depend on longitudinal, multi-omics approaches and biomarker-driven stratification to enable precision-based microbiota-targeted interventions.
- 19 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (2(50))
Open AccessTHE GUT–BRAIN AXIS IN AUTISM SPECTRUM DISORDER: MICROBIOTA, IMMUNE DYSREGULATION, AND THERAPEUTIC PERSPECTIVES
Background: Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by persistent difficulties in social communication, restricted and repetitive behaviors, and a high prevalence of co-occurring gastrointestinal, metabolic, and immune disturbances. Increasing evidence suggests that the gut–brain axis—a bidirectional communication network linking intestinal microbiota, immune signaling, metabolic pathways, and neural circuits—may play an important modulatory role in ASD-related neurodevelopmental processes. Scope: This review synthesizes current evidence on gut–brain axis physiology and examines how alterations in microbiota composition and function intersect with immune dysregulation, microbial metabolite signaling, and neurodevelopment in ASD. Findings from clinical studies, preclinical mechanistic research, and emerging microbiota-targeted therapeutic approaches are integrated to provide a systems-level perspective on microbiota–immune–brain interactions. Key Findings: Individuals with ASD frequently exhibit altered gut microbial diversity and composition, accompanied by functional disruptions in microbial metabolite pathways, including short-chain fatty acid and tryptophan metabolism. These changes are associated with impaired intestinal barrier integrity, systemic immune activation, neuroinflammatory signaling, and microglial dysfunction, processes that may contribute to excitatory–inhibitory imbalance and altered synaptic plasticity in the central nervous system. Microbiota-targeted interventions—such as probiotics, dietary modification, and fecal microbiota transplantation—demonstrate preliminary benefits for gastrointestinal symptoms and selected behavioral outcomes, although clinical evidence remains heterogeneous and limited. Conclusions: Current evidence supports a multifactorial model in which gut microbiota alterations act as modulatory amplifiers of neurodevelopmental vulnerability in ASD rather than as primary causal factors. Interactions among microbial metabolism, immune regulation, environmental exposures, and developmental timing appear central to this process. Future progress will depend on longitudinal, multi-omics approaches and biomarker-driven stratification to enable precision-based microbiota-targeted interventions.
- Open Access
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
MODERN SURGICAL TECHNIQUES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW
Aims: To systematically review randomized evidence on modern minimally invasive and endoscopic techniques for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), focusing on clinical efficacy, safety, perioperative outcomes, preservation of sexual/ejaculatory function, and durability compared with TURP or sham. Methods: We conducted a systematic PubMed search (2020–2025) using predefined terms for BPH surgery and randomized controlled trials. Main findings from eligible articles were summarized. Results: The review identified 41 randomized controlled trials evaluating nine modern techniques (endoscopic enucleation, laser vaporization, Aquablation, Rezūm water vapor thermal therapy, prostatic urethral lift/PUL, transperineal laser ablation/TPLA, temporary nitinol device/iTind, drug-coated balloon/Optilume, and prostatic artery embolisation/PAE), comprising thousands of men with moderate-to-severe LUTS. Endoscopic enucleation and Aquablation showed durable, TURP-like or superior improvements in IPSS, QoL, Qmax, and PVR, particularly in large prostates (>80 mL), with better perioperative outcomes. Minimally invasive surgical therapies (MISTs) provided meaningful symptom relief and excellent preservation of sexual/ejaculatory function, while PAE had lower objective efficacy and higher reintervention rates. Serious complications were uncommon across all techniques. Conclusions: Current evidence supports these modern techniques as valuable alternatives to TURP, enabling individualized treatment based on prostate volume and patient priorities for sexual function, recovery, and durability. However, heterogeneity in follow-up duration, variable prostate-size criteria, and the limited number of large head-to-head trials restrict definitive conclusions. Further adequately powered, long-term randomized studies are needed to better define the optimal role of each modality in clinical practice.
- 26 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessMODERN SURGICAL TECHNIQUES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW
Aims: To systematically review randomized evidence on modern minimally invasive and endoscopic techniques for treating lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), focusing on clinical efficacy, safety, perioperative outcomes, preservation of sexual/ejaculatory function, and durability compared with TURP or sham. Methods: We conducted a systematic PubMed search (2020–2025) using predefined terms for BPH surgery and randomized controlled trials. Main findings from eligible articles were summarized. Results: The review identified 41 randomized controlled trials evaluating nine modern techniques (endoscopic enucleation, laser vaporization, Aquablation, Rezūm water vapor thermal therapy, prostatic urethral lift/PUL, transperineal laser ablation/TPLA, temporary nitinol device/iTind, drug-coated balloon/Optilume, and prostatic artery embolisation/PAE), comprising thousands of men with moderate-to-severe LUTS. Endoscopic enucleation and Aquablation showed durable, TURP-like or superior improvements in IPSS, QoL, Qmax, and PVR, particularly in large prostates (>80 mL), with better perioperative outcomes. Minimally invasive surgical therapies (MISTs) provided meaningful symptom relief and excellent preservation of sexual/ejaculatory function, while PAE had lower objective efficacy and higher reintervention rates. Serious complications were uncommon across all techniques. Conclusions: Current evidence supports these modern techniques as valuable alternatives to TURP, enabling individualized treatment based on prostate volume and patient priorities for sexual function, recovery, and durability. However, heterogeneity in follow-up duration, variable prostate-size criteria, and the limited number of large head-to-head trials restrict definitive conclusions. Further adequately powered, long-term randomized studies are needed to better define the optimal role of each modality in clinical practice.
- Open Access
- 22 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
OVERTRAINING SYNDROME AND MENTAL HEALTH IN ATHLETES - A LITERATURE REVIEW
Overtraining Syndrome (OTS) is a complex biopsychosocial condition arising from a chronic imbalance between training load and recovery. OTS produces numerous psychiatric symptoms that remain systematically underrecognized in clinical practice. This review examines the neurobiological mechanisms linking OTS to mental health disorders, characterizes its psychiatric symptomatology, clarifies differential diagnosis with primary psychiatric conditions, and synthesizes current evidence on monitoring, prevention, and management. OTS affects numerous elite athletes during their careers, with a relapse rate of 80–90% within three years of recovery. Its neurobiological mechanisms — HPA axis exhaustion, serotonergic receptor dysregulation, neuroinflammatory activation, and autonomic nervous system dysfunction — overlap substantially with those of major depressive disorder, providing a mechanistic basis for the extensive psychiatric comorbidity observed clinically. OTS presents across three dimensions: affective and anxiety symptoms, neurocognitive and somatic impairment, and burnout. Differential diagnosis requires systematic exclusion of primary psychiatric disorders, Relative Energy Deficiency in Sport (RED-S), and organic pathology. Prevention and management form a continuum encompassing psychological monitoring, primary prevention strategies, and — in established OTS — multidisciplinary treatment including psychiatric and psychological interventions. OTS is a biopsychosocial condition whose psychiatric dimension is clinically substantial yet underdiagnosed. Its neurobiological overlap with major depressive disorder warrants integration of psychiatric expertise into the routine evaluation and management of overtrained athletes. The field remains constrained by the absence of validated diagnostic criteria and evidence-based psychological interventions — gaps that sports psychiatry is well-positioned to address.
- 22 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessOVERTRAINING SYNDROME AND MENTAL HEALTH IN ATHLETES - A LITERATURE REVIEW
Overtraining Syndrome (OTS) is a complex biopsychosocial condition arising from a chronic imbalance between training load and recovery. OTS produces numerous psychiatric symptoms that remain systematically underrecognized in clinical practice. This review examines the neurobiological mechanisms linking OTS to mental health disorders, characterizes its psychiatric symptomatology, clarifies differential diagnosis with primary psychiatric conditions, and synthesizes current evidence on monitoring, prevention, and management. OTS affects numerous elite athletes during their careers, with a relapse rate of 80–90% within three years of recovery. Its neurobiological mechanisms — HPA axis exhaustion, serotonergic receptor dysregulation, neuroinflammatory activation, and autonomic nervous system dysfunction — overlap substantially with those of major depressive disorder, providing a mechanistic basis for the extensive psychiatric comorbidity observed clinically. OTS presents across three dimensions: affective and anxiety symptoms, neurocognitive and somatic impairment, and burnout. Differential diagnosis requires systematic exclusion of primary psychiatric disorders, Relative Energy Deficiency in Sport (RED-S), and organic pathology. Prevention and management form a continuum encompassing psychological monitoring, primary prevention strategies, and — in established OTS — multidisciplinary treatment including psychiatric and psychological interventions. OTS is a biopsychosocial condition whose psychiatric dimension is clinically substantial yet underdiagnosed. Its neurobiological overlap with major depressive disorder warrants integration of psychiatric expertise into the routine evaluation and management of overtrained athletes. The field remains constrained by the absence of validated diagnostic criteria and evidence-based psychological interventions — gaps that sports psychiatry is well-positioned to address.
- Open Access
- 21 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
GLP-1 RECEPTOR AGONISTS AND ALCOHOL USE DISORDER: PROMISE FOR A NEW TREATMENT APPROACH
The role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as effective glucose-lowering and nephroprotective agents in type 2 diabetes is well established. Their emergence as treatments for obesity is considerably more recent. In the short time since this indication was approved, these medications have attracted considerable attention, and their use in clinical practise has expanded rapidly. Amid this rapid expansion, clinicians have encountered growing anecdotal reports from patients taking GLP-1RAs describing unexpected improvements in substance use behaviours. Such reports are consistent with a growing body of preclinical evidence demonstrating that GLP-1RAs reduce intake of alcohol and other addictive substances. Whether preclinical observations can be replicated in human studies is currently being tested in clinical trials. One prevailing hypothesis suggests that glucagon-like peptide-1 (GLP-1) exerts its effects via central mechanisms, including, at least in part, modulation of dopamine transmission. Studies imply that activation of central glucagon-like peptide -1 receptors (GLP-1Rs) functionally regulates the mesolimbic reward pathway and reduces addiction-like behaviors in rodent models. This narrative review summarizes the existing evidence regarding the effects of GLP-1RAs on alcohol consumption. Relevant studies published between January 2015 and March 2026 were identified via literature search. Collectively, the evidence supporting GLP-1RAs for the treatment of AUD is promising yet inconsistent, with randomized clinical trials yielding mixed results for the primary outcome of reduced alcohol consumption. Although current findings do not justify changes to clinical practice, they point toward potential benefits of GLP-1RAs, extending beyond glycemic and weight control, particularly among patients with AUD.
- 21 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (2(50))
Open AccessGLP-1 RECEPTOR AGONISTS AND ALCOHOL USE DISORDER: PROMISE FOR A NEW TREATMENT APPROACH
The role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as effective glucose-lowering and nephroprotective agents in type 2 diabetes is well established. Their emergence as treatments for obesity is considerably more recent. In the short time since this indication was approved, these medications have attracted considerable attention, and their use in clinical practise has expanded rapidly. Amid this rapid expansion, clinicians have encountered growing anecdotal reports from patients taking GLP-1RAs describing unexpected improvements in substance use behaviours. Such reports are consistent with a growing body of preclinical evidence demonstrating that GLP-1RAs reduce intake of alcohol and other addictive substances. Whether preclinical observations can be replicated in human studies is currently being tested in clinical trials. One prevailing hypothesis suggests that glucagon-like peptide-1 (GLP-1) exerts its effects via central mechanisms, including, at least in part, modulation of dopamine transmission. Studies imply that activation of central glucagon-like peptide -1 receptors (GLP-1Rs) functionally regulates the mesolimbic reward pathway and reduces addiction-like behaviors in rodent models. This narrative review summarizes the existing evidence regarding the effects of GLP-1RAs on alcohol consumption. Relevant studies published between January 2015 and March 2026 were identified via literature search. Collectively, the evidence supporting GLP-1RAs for the treatment of AUD is promising yet inconsistent, with randomized clinical trials yielding mixed results for the primary outcome of reduced alcohol consumption. Although current findings do not justify changes to clinical practice, they point toward potential benefits of GLP-1RAs, extending beyond glycemic and weight control, particularly among patients with AUD.